<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        DiGeorge (22q11.2 deletion) syndrome: Clinical features and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christine M Seroogy, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer M Puck, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3601566">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         DiGeorge syndrome (DGS) is a constellation of signs and symptoms associated with defective development of the pharyngeal pouch system. Most cases are caused by a heterozygous chromosomal deletion at 22q11.2. Chromosome 22q11.2 deletion syndrome (22qDS) includes DGS and other similar syndromes, such as velocardiofacial syndrome. The classic triad of features of DGS on presentation is conotruncal cardiac anomalies, hypoplastic thymus, and hypocalcemia (resulting from parathyroid hypoplasia).
        </p>
        <p>
         Thymic defects in DGS result in a range of T cell deficits. Most patients with DGS have mild defects in T cell numbers and are not severely immunodeficient. Approximately 1 percent, however, have a complete absence of thymic tissue and profound immunodeficiency. This form of DGS, called complete DGS, is a type of congenital athymia with a severe combined immunodeficiency (SCID) phenotype and is life threatening if not corrected with immune reconstitution by thymic tissue implantation or potentially hematopoietic cell transplantation in some instances. (See
         <a class="medical medical_review" href="/z/d/html/115988.html" rel="external">
          "Hematopoietic cell transplantation for severe combined immunodeficiencies"
         </a>
         .)
        </p>
        <p>
         This topic reviews the clinical features and diagnosis of DGS. The epidemiology, pathogenesis, management, and prognosis of patients with DGS are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3909.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Management and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25716807">
         <span class="h1">
          CLINICAL PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The classic triad of features of DGS on presentation is conotruncal cardiac anomalies, hypoplastic thymus, and hypocalcemia, and they are diagnosed in early life [
         <a href="#rid1">
          1
         </a>
         ]. However, the phenotype is quite variable  (
         <a class="graphic graphic_table graphicRef72911" href="/z/d/graphic/72911.html" rel="external">
          table 1
         </a>
         ), and there may be marked differences between affected persons, even within a single family [
         <a href="#rid2">
          2-7
         </a>
         ]. A broad spectrum characterizes the presence and severity of individual features, and the severity of each feature appears to be independent of other features. Older children with DGS may be detected through clinics for congenital heart defects or craniofacial clinics, may be referred to developmental specialists for poor school performance, or may be diagnosed due to frequent infections or autoimmune conditions.
        </p>
        <p class="headingAnchor" id="H12143262">
         <span class="h2">
          Cardiac anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conotruncal cardiac defects occur in approximately 80 percent of DGS patients and, when present, are typically the initial abnormalities noted [
         <a href="#rid2">
          2,3,5
         </a>
         ]. The term "conotruncal" refers to the distal portion of the fetal heart (trunco-aortic sac) at an early stage in development. The aortic and pulmonary roots subsequently develop from this area, and defects in these structures are referred to as conotruncal defects.
        </p>
        <p>
         The most common cardiac defects account for two-thirds of the cardiac anomalies seen in patients with DGS and include the following [
         <a href="#rid2">
          2,3,5,8,9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Interrupted aortic arch
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Truncus arteriosus
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tetralogy of Fallot
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrial or ventricular septal defects (ASDs or VSDs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vascular rings
        </p>
        <p>
        </p>
        <p>
         The first three defects listed cause cyanotic heart disease in the newborn. Infants with an interrupted aortic arch may present with differential cyanosis, in which the upper half of the body is pink and the lower half is blue. (See
         <a class="medical medical_review" href="/z/d/html/5780.html" rel="external">
          "Cardiac causes of cyanosis in the newborn"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14588.html" rel="external">
          "Truncus arteriosus"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1536.html" rel="external">
          "Congenital and pediatric coronary artery abnormalities"
         </a>
         .)
        </p>
        <p>
         Most children with small ASDs and VSDs are asymptomatic, but infants with large defects may present with heart failure, failure to thrive, and/or respiratory distress. (See
         <a class="medical medical_review" href="/z/d/html/5754.html" rel="external">
          "Isolated atrial septal defects (ASDs) in children: Classification, clinical features, and diagnosis", section on 'Presentation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5787.html" rel="external">
          "Isolated ventricular septal defects (VSDs) in infants and children: Anatomy, clinical features, and diagnosis", section on 'Presentation'
         </a>
         .)
        </p>
        <p>
         The clinical presentation of vascular rings varies depending upon the degree of tracheal and esophageal compression and can range from critical airway obstruction to stridor and feeding issues. Patients with incomplete vascular rings may be asymptomatic. (See
         <a class="medical medical_review" href="/z/d/html/5757.html" rel="external">
          "Vascular rings and slings"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1536.html" rel="external">
          "Congenital and pediatric coronary artery abnormalities"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12143276">
         <span class="h2">
          Hypocalcemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypocalcemia, resulting from underdevelopment of the parathyroid glands, is another potentially life-threatening manifestation of DGS. This develops in the newborn period in up to 60 percent of DGS patients and may present with jitteriness, tetany, or seizures, with low serum calcium, elevated serum phosphorus, and very low parathyroid hormone levels. (See
         <a class="medical medical_review" href="/z/d/html/833.html" rel="external">
          "Clinical manifestations of hypocalcemia"
         </a>
         .)
        </p>
        <p>
         Complications of hypocalcemia are unusual later in life, secondary to presumed compensatory hyperplasia of existing parathyroid tissue. However, hypocalcemia can be precipitated by extreme stress in older patients [
         <a href="#rid10">
          10
         </a>
         ]. Rarely, complications of hypocalcemia are the presenting symptoms in adults with undiagnosed 22qDS [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2050.html" rel="external">
          "Parathyroid hormone secretion and action"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4519623">
         <span class="h2">
          Hypoplastic/aplastic thymus
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most patients with DGS, the thymus is present, although it is often reported as hypoplastic. However, the definition of thymic hypoplasia is inexact since there are limited studies, particularly in children, to support the definition of a diminished size of the thymus in any condition or in normal individuals [
         <a href="#rid12">
          12,13
         </a>
         ]. The thymus is completely absent in a rare subset of patients with DGS. One study characterizing fetal thymic size for at-risk pregnancies found that the presence of normal thymic tissue mass was associated with normal or near-normal T cell counts at birth [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Thymic hypoplasia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Immune function'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4670119">
         <span class="h2">
          Immunodeficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunodeficiency is common in patients with DGS and can range from prolonged and recurrent sinopulmonary infections (often termed partial DGS) to congenital athymia (a severe combined immunodeficiency [SCID] like phenotype termed complete DGS). The severity of the immunodeficiency is related to the degree of thymic function. (See
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Thymic hypoplasia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Immune function'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5815068">
         <span class="h3">
          Complete DGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complete DGS is found in less than 1 percent of patients with 22qDS and is a form of congenital athymia. The thymus is absent, and the T cell count is &lt;3 standard deviations below normal for age (typically &lt;50 CD3+ T cells/mm
         <sup>
          3
         </sup>
         ) in these patients. In a large series of patients with complete DGS, 52 percent had an identifiable 22q11.2 deletion, while the remaining 48 percent did not have an identifiable chromosomal problem at the time of the study [
         <a href="#rid15">
          15
         </a>
         ]. Infants with complete DGS are detected by SCID newborn screening (NBS) using an assay for T cell receptor excision circles (TRECs), a biomarker of T cell development/thymopoiesis [
         <a href="#rid16">
          16,17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">
          "Newborn screening for inborn errors of immunity", section on 'Screening for SCID and other T cell defects'
         </a>
         .)
        </p>
        <p>
         In the absence of screening, infants with complete DGS are diagnosed following the development of recurrent severe infections, chronic diarrhea, and failure to thrive. This form of DGS is fatal unless recognized promptly after birth and treated with thymic tissue implantation or bone marrow transplant. (See
         <a class="local">
          'Evaluation in neonates'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">
          "Severe combined immunodeficiency (SCID): An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3909.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Management and prognosis", section on 'Immunologic management of complete DGS'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H665479">
         <span class="h4">
          "Atypical" complete DGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A subset of patients with severe T cell deficiency, detectable by SCID newborn screening, present with or develop a leaky form of SCID phenotype, typically referred to as atypical complete DGS [
         <a href="#rid18">
          18-21
         </a>
         ]. These patients have oligoclonal populations of T cells detectable in the peripheral blood, lymphadenopathy, and a generalized dermatitis [
         <a href="#rid22">
          22
         </a>
         ]. Their T cells respond poorly to mitogens in vitro, and there is no evidence for maternal engraftment. Patients with atypical complete DGS can present with erythroderma, oligoclonal T cell expansion, lymphadenopathy, and elevated serum immunoglobulin E (IgE) levels and may be best classified as Omenn-like syndrome. (See
         <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">
          "T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T-B-NK+ SCID without radiation sensitivity due to RAG defects (includes most cases of Omenn syndrome)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">
          "T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'Omenn syndrome phenotype'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6296705">
         <span class="h3">
          Partial DGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Overall, approximately 75 percent of patients with 22qDS have some degree of thymic insufficiency [
         <a href="#rid2">
          2
         </a>
         ]. Partial DGS infants with the lowest production of T cells will be identified by SCID NBS [
         <a href="#rid16">
          16
         </a>
         ]. The exact proportion of cases detected by NBS depends upon the screening TREC cutoff, which is determined by individual state screening programs in the United States. Impaired T cell production occurs in most infants with partial DGS, although CD3+ T cell counts tend to improve gradually or stabilize over time and can approach age-related normal levels. The improvement in CD3+ T cell counts reflects decreased age-related decline in T cell counts and increased accumulation of memory T cells secondary to lymphocytic homeostatic proliferation [
         <a href="#rid23">
          23
         </a>
         ]. T cell function may also be abnormal, although the deficiency is not usually severe [
         <a href="#rid24">
          24
         </a>
         ]. Most patients with partial DGS do not suffer from opportunistic or life-threatening infections [
         <a href="#rid25">
          25
         </a>
         ]. However, many patients with partial DGS have a history of recurrent sinopulmonary infections and prolonged respiratory viral illnesses [
         <a href="#rid26">
          26
         </a>
         ]. Humoral immunodeficiencies are associated with partial DGS, including an increased prevalence of immunoglobulin A (IgA) deficiency and functional antibody defects (ie, polysaccharide antibody deficiency) [
         <a href="#rid27">
          27-30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Partial DGS'
         </a>
         .)
        </p>
        <p>
         In one study, up to one-third of patients had either recurrent sinusitis or otitis media, and a minority had bronchitis or pneumonia [
         <a href="#rid29">
          29
         </a>
         ]. Recurrent and chronic sinusitis appears to be related to palatal abnormalities or gastroesophageal reflux in some patients, although polysaccharide antibody deficiency is also seen. (See
         <a class="medical medical_review" href="/z/d/html/3965.html" rel="external">
          "Specific antibody deficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3963.html" rel="external">
          "Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7568451">
         <span class="h2">
          Other immune-related problems
         </span>
         <span class="headingEndMark">
          —
         </span>
         An increased incidence of autoimmune and atopic disease is seen in patients with DGS.
        </p>
        <p class="headingAnchor" id="H7568458">
         <span class="h3">
          Autoimmune disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple retrospective and prospective studies have demonstrated an increased incidence of autoimmune phenomenon in patients with DGS and 22qDS, estimated at 10 percent [
         <a href="#rid27">
          27,29,31-38
         </a>
         ], suggesting an underlying defect in immune regulation [
         <a href="#rid23">
          23,39,40
         </a>
         ]. Studies are ongoing to better define the mechanism(s) of immune dysregulation. Impaired central and peripheral tolerance is implicated as the underlying mechanism for increased autoimmune disease, but this remains poorly defined [
         <a href="#rid41">
          41-43
         </a>
         ]. A case-control, multicenter study demonstrated distinct immune phenotypes in patients with DGS and autoimmune hemolytic anemia (AIHA) compared with those without AIHA. The immune differences predated the development of AIHA. This observation implies that a patient's immunophenotype may allow prognostication for the risk of developing autoimmune disease [
         <a href="#rid44">
          44
         </a>
         ]. The autoimmune diseases that are reported at an increased frequency in this population include autoimmune cytopenias, arthritis, enteropathy, and autoimmune thyroid disease. Several case reports have documented that an autoimmune manifestation was the presenting symptom leading to the diagnosis of 22qDS [
         <a href="#rid45">
          45,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Partial DGS'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16362.html" rel="external">
          "Autoimmunity in patients with inborn errors of immunity/primary immunodeficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7568588">
         <span class="h3">
          Allergic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atopic disease may also be a feature of 22qDS. One study demonstrated an increased incidence of asthma and eczema, but not allergic rhinitis, in 22qDS patients compared with the sibling control group [
         <a href="#rid47">
          47
         </a>
         ]. The underlying proposed mechanism is preferential skewing toward T helper cell type 2 (Th2) differentiation due to the increased homeostatic proliferation observed in 22qDS patients [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5815285">
         <span class="h2">
          Craniofacial abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Possible facial abnormalities include low-set and posteriorly rotated ears, ocular hypertelorism, and a bulbous nasal tip  (
         <a class="graphic graphic_table graphicRef54237" href="/z/d/graphic/54237.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef68022" href="/z/d/graphic/68022.html" rel="external">
          picture 1
         </a>
         ). These phenotypic findings are not specific for DGS and can be less pronounced in some populations [
         <a href="#rid48">
          48
         </a>
         ]. Similar features may be seen in patients with other 22qDS, such as velocardiofacial syndrome, Opitz G/BBB syndrome, and Cayler cardiofacial syndrome. Nasal dysmorphism, for example, was the one consistent finding in a series of 225 patients with 22q11.2 deletions [
         <a href="#rid49">
          49
         </a>
         ]. The facial features in DGS often become less pronounced with age  (
         <a class="graphic graphic_picture graphicRef68022" href="/z/d/graphic/68022.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2926.html" rel="external">
          "Syndromes with craniofacial abnormalities", section on 'Velocardiofacial (Shprintzen) syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4519769">
         <span class="h2">
          Palatal and related problems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other findings in infants with DGS include palatal and laryngotracheal abnormalities and related feeding difficulties [
         <a href="#rid3">
          3,50,51
         </a>
         ]. Palatal abnormalities include overt cleft palate and submucosal cleft palate. Velopharyngeal insufficiency in patients with DGS can be due to structural causes (eg, cleft palate) and/or neuromuscular problems (eg, hypotonia) [
         <a href="#rid52">
          52
         </a>
         ]. The most common findings of velopharyngeal insufficiency are hypernasal speech and nasal regurgitation [
         <a href="#rid1">
          1
         </a>
         ]. Some of these signs and symptoms are subtle and may not come to medical attention. The causes, clinical features, and diagnosis of swallowing dysfunction are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6769.html" rel="external">
          "Etiology, prenatal diagnosis, obstetric management, and recurrence of cleft lip and/or palate"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/616.html" rel="external">
          "Etiology of speech and language disorders in children", section on 'Resonance disorders'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14537.html" rel="external">
          "Aspiration due to swallowing dysfunction in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5816053">
         <span class="h2">
          Developmental and behavioral problems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Developmental delay occurs in the vast majority of patients with 22qDS, and speech delay is especially common  (
         <a class="graphic graphic_table graphicRef72911" href="/z/d/graphic/72911.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,3,4,6,37,53-57
         </a>
         ]. Intelligence ranges from normal to moderate intellectual disability. Patients typically score higher on verbal than performance measures initially, but a greater decline is seen over time in verbal domains compared with performance domains [
         <a href="#rid58">
          58
         </a>
         ]. Problems in social emotional functioning and inhibition and attention disorders may occur. Deficits in motor functioning have also been reported.
        </p>
        <p class="headingAnchor" id="H7568764">
         <span class="h2">
          Other anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may also present with skeletal (eg, scoliosis) and structural genitourinary tract abnormalities [
         <a href="#rid1">
          1,3,50,59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5816114">
         <span class="h2">
          Findings in adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adults with 22qDS have not been extensively studied [
         <a href="#rid60">
          60,61
         </a>
         ], and ascertainment bias is probably present in analyses of retrospective case series. Population-based prospective studies on adults with 22qDS are needed to better define characteristics and assist with clinical management.
        </p>
        <p>
         In the largest retrospective series of 126 adults, 60 percent were parents of affected children, and the others were patients in craniofacial, cardiology, genetics, and psychiatry clinics [
         <a href="#rid61">
          61
         </a>
         ]. Compared with a large series of children with 22qDS, adults had significantly lower rates of major cardiac anomalies (30 percent) and higher rates of palatal abnormalities (88 percent), intellectual disabilities (94 percent), and psychiatric conditions (36 percent). The most common findings were minor facial anomalies (99 percent) and hypernasal speech  (
         <a class="graphic graphic_picture graphicRef52371" href="/z/d/graphic/52371.html" rel="external">
          picture 2
         </a>
         ). Psychiatric disorders included schizophrenia, schizoaffective disorder, and major depression. Assessment of longitudinal cognitive evaluations for 411 patients with 22qDS found that a steeper decline in cognitive function, particularly in the verbal domains (beginning around 11 years of age in one series), is associated with the development of a psychotic disorder [
         <a href="#rid58">
          58
         </a>
         ]. Hypocalcemia was reported in 15 percent and ranged in severity and age of onset (birth to 33 years). Thrombocytopenia or recurrent epistaxis was observed in 12 percent of patients; both findings are noted less frequently in infants.
        </p>
        <p>
         A prospective case-control study with 309 adults with 22qDS aimed to determine overall mortality risk [
         <a href="#rid62">
          62
         </a>
         ]. Compared with their unaffected siblings, persons with 22qDS were found to have a significantly higher risk for mortality that was independently associated with global effects of 22qDS and complex congenital heart disease.
        </p>
        <p class="headingAnchor" id="H11654078">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of DGS is based upon reduced numbers of CD3+ T cells, combined with either characteristic clinical findings (eg, congenital cardiac anomalies, hypocalcemia) or a demonstrated deletion in chromosome 22q11.2 (22qDS). Proposed criteria define three diagnoses: definite, probable, and possible DGS  (
         <a class="graphic graphic_table graphicRef55190" href="/z/d/graphic/55190.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid63">
          63
         </a>
         ]. Approximately 90 percent of patients with DGS have heterozygous deletions in chromosome 22q11.2, although this deletion is less common in those with complete DGS. (See
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Genetic abnormalities'
         </a>
         and
         <a class="local">
          'Genetic analysis'
         </a>
         below.)
        </p>
        <p>
         Complete DGS is diagnosed by the presence of severe immunodeficiency (CD3+T cell numbers &lt;50/mm
         <sup>
          3
         </sup>
         to absent and lack of proliferation to mitogens) and athymia. A 22q11.2 deletion is identified in approximately 50 percent of patients with complete DGS [
         <a href="#rid15">
          15,64
         </a>
         ]. Complete DGS is also identified on newborn screening (NBS) for severe combined immunodeficiency (SCID) that examines for the presence of T cell receptor excision circles (TRECs). (See
         <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">
          "Newborn screening for inborn errors of immunity", section on 'Screening for SCID and other T cell defects'
         </a>
         .)
        </p>
        <p>
         TREC findings in DGS have not been systematically studied. However, excision circles were entirely absent in the few cases of complete DGS in which TREC results were reported [
         <a href="#rid17">
          17,65
         </a>
         ]. Additionally, compiled data from 11 states that screen for SCID reported positive screens in infants with partial DGS [
         <a href="#rid16">
          16
         </a>
         ]. Of the over three million infants screened, 78 were found to have non-SCID T cell lymphopenia and DGS/22qDS. A retrospective analysis of stored NBS blood filter cards from 48 known patients with 22qDS found abnormal TREC values in 19 percent of subjects [
         <a href="#rid66">
          66
         </a>
         ]. Population-based prospective studies are necessary to determine if the infants with DGS/22qDS detected by NBS SCID have a more severe immune phenotype or if early detection results in improved clinical care/outcomes and quality of life.
        </p>
        <p>
         NBS for genetic disorders is rapidly evolving as molecular testing improves and costs decrease. Test platforms to screen for 22qDS on NBS filter cards have been developed [
         <a href="#rid67">
          67
         </a>
         ]. Discussions continue to reach consensus on population-based NBS for 22qDS and the associated ethical issues in screening for a genetic disorder with such a varied phenotype.
        </p>
        <p class="headingAnchor" id="H25718520">
         <span class="h2">
          Evaluation in neonates
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation for DGS should be considered for any neonate with a conotruncal heart lesion, hypocalcemia, and/or cleft palate.
        </p>
        <p class="headingAnchor" id="H25718527">
         <span class="h3">
          Initial studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants with suggestive signs and symptoms  (
         <a class="graphic graphic_table graphicRef72911" href="/z/d/graphic/72911.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef54237" href="/z/d/graphic/54237.html" rel="external">
          table 2
         </a>
         ) should have the following performed [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac evaluation and echocardiogram (urgently)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum calcium and phosphorus levels
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood cell count with differential to evaluate for lymphopenia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiograph to evaluate for absence of a thymic shadow  (
         <a class="graphic graphic_diagnosticimage graphicRef67690" href="/z/d/graphic/67690.html" rel="external">
          image 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renal ultrasound to assess for structural genitourinary tract abnormalities
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         T and B cell phenotyping by flow cytometry
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin levels
        </p>
        <p>
        </p>
        <p>
         The absence of a thymic shadow on chest imaging suggests some form of SCID, although the presence of a normal thymic shadow does not exclude DGS. Diminished thymic tissue is suggestive of an immunodeficiency. However, this is an insensitive test since stress or infection can lead to thymic involution.
        </p>
        <p class="headingAnchor" id="H25718534">
         <span class="h3">
          Advanced studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the thymus appears to be small or absent, the NBS SCID screen is positive, and lymphopenia is present, further evaluation of T and B cell quantification and function should be done quickly to assure that patients with complete DGS are identified. (See
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Immune function'
         </a>
         .)
        </p>
        <p>
         This evaluation should include the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In vitro T cell proliferation in response to mitogens (such as the plant lectins phytohemagglutinin [PHA] or anti-CD3 antibody). Note that proliferative responses to neoantigens (such as vaccine antigens and
         <em>
          Candida
         </em>
         ) are not useful in neonates who have not been exposed to these agents and have a maturing immune system but can be used in older children and adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Analysis of TRECs is helpful for infants suspected of having complete DGS [
         <a href="#rid23">
          23,68
         </a>
         ]. TREC analysis quantitates thymic output of T cells and is a more sensitive measure of thymic function than imaging of the thymus. If TREC values are low alongside low T cell counts, determination of the frequency of naïve T cells by measurement of expression of the cell surface marker CD45RA+ on CD4+ T cells helps to distinguish between complete DGS and a profound initial partial DGS presentation [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">
          "Newborn screening for inborn errors of immunity", section on 'Overview of TREC screening test'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3905.html" rel="external">
          "DiGeorge (22q11.2 deletion) syndrome: Epidemiology and pathogenesis", section on 'Complete DGS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flow cytometry can be used to determine T cell repertoire (T cell receptor [TCR] V-beta chain diversity), and additional analysis for recent thymic emigrants should be considered (ie, CD45RA+CD62L+ expression).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         B cell function can be assessed by measuring immunoglobulin M (IgM) levels. In complete DGS, IgM is low or absent, as seen in patients with SCID. Immunoglobulin G (IgG) in neonates born after 34 weeks of gestation is of mixed maternal/infant origin, and IgA levels can be undetectable in normal infants, rising only after several months of age.
        </p>
        <p>
        </p>
        <p>
         The laboratory evaluation of T and B cell function is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3903.html" rel="external">
          "Laboratory evaluation of the immune system"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25718576">
         <span class="h2">
          Evaluation in older children and adults
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of DGS should be considered in older children and adults with a family history of DGS and/or consistent clinical findings, including characteristic facial features, developmental/intellectual disability, conotruncal cardiac anomalies, palatal anomalies and hypernasal speech, and psychiatric problems  (
         <a class="graphic graphic_table graphicRef72911" href="/z/d/graphic/72911.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef54237" href="/z/d/graphic/54237.html" rel="external">
          table 2
         </a>
         ). Clinical manifestations in different age groups are reviewed above [
         <a href="#rid61">
          61,69,70
         </a>
         ]. (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Findings in adults'
         </a>
         above.)
        </p>
        <p>
         Parameters for the initial assessment of older children and adults with 22qDS have been proposed [
         <a href="#rid60">
          60
         </a>
         ]. In addition to a comprehensive medical history and physical examination, the suggested initial evaluation includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychiatric and cognitive assessment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consultation with medical geneticist or genetics clinic experienced in 22qDS
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic analysis, such as fluorescence in situ hybridization (FISH), multiplex ligation-dependent probe amplification (MLPA), single nucleotide polymorphism (SNP) array, or comparative genomic hybridization (CGH) microarray
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood cell count and differential
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endocrine studies, including measurements of thyroid-stimulating hormone, pH-corrected ionized calcium, parathyroid hormone, and serum creatinine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal ultrasound to evaluate for renal abnormalities
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Echocardiogram
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1431580">
         <span class="h2">
          Genetic analysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic studies are necessary to define the molecular basis for DGS, although they are not required to make a definitive diagnosis  (
         <a class="graphic graphic_table graphicRef55190" href="/z/d/graphic/55190.html" rel="external">
          table 3
         </a>
         ). An appropriate initial step is to assay for a microdeletion at the critical DGS region of chromosome 22. FISH, using a probe specific for the critical deleted region in chromosome 22q11.2, was the primary test for genetic diagnosis of 22qDS  (
         <a class="graphic graphic_figure graphicRef65172" href="/z/d/graphic/65172.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         FISH is being replaced with other more rapid and sensitive molecular test modalities including MLPA, SNP array, and CGH microarray. The last two tests offer the advantage of interrogating the entire genome rather than only the chromosome 22q11.2 region, thereby giving information about copy number variants (CNVs) in other chromosomes that can be associated with DGS-like conditions, such as 10p13.14 microdeletion syndrome or CHARGE (
         <strong>
          c
         </strong>
         oloboma of the eye,
         <strong>
          h
         </strong>
         eart anomalies, choanal
         <strong>
          a
         </strong>
         tresia,
         <strong>
          r
         </strong>
         etardation,
         <strong>
          g
         </strong>
         enital and
         <strong>
          e
         </strong>
         ar anomalies) syndrome secondary to microdeletions affecting chromodomain helicase DNA-binding protein 7 (
         <em>
          CHD7
         </em>
         ) (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below). Comprehensive molecular assays, such as CGH microarray, that broadly screen for CNVs are widely available and may have lower cost and faster turnaround time than FISH testing for 22q11.2 deletions, depending upon the institution or laboratory.
        </p>
        <p>
         If testing is negative for 22q11.2 deletions, then gene sequencing of the T-box 1 transcription factor gene (
         <em>
          TBX1
         </em>
         ) is recommended to look for disease-associated variants not detectable by the above testing. Heterozygous variants in
         <em>
          TBX1
         </em>
         have been reported to cause most, if not all, features of DGS [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25718590">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the complexity of the branchial-pharyngeal developmental sequence, it is not surprising that multiple genetic and teratogenic effects can result in common phenotypic outcomes.
        </p>
        <p class="headingAnchor" id="H25718597">
         <span class="h2">
          Other congenital syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several distinct clinical syndromes share phenotypic similarities with 22qDS, including Zellweger, CHARGE (
         <strong>
          c
         </strong>
         oloboma of the eye,
         <strong>
          h
         </strong>
         eart anomalies, choanal
         <strong>
          a
         </strong>
         tresia,
         <strong>
          r
         </strong>
         etardation,
         <strong>
          g
         </strong>
         enital and
         <strong>
          e
         </strong>
         ar anomalies), and Opitz G/BBB syndromes [
         <a href="#rid2">
          2,72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25718604">
         <span class="h3">
          Zellweger syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Zellweger syndrome is a peroxisomal disorder that presents at birth with a typical craniofacial dysmorphism  (
         <a class="graphic graphic_picture graphicRef72662" href="/z/d/graphic/72662.html" rel="external">
          picture 3
         </a>
         ). Unlike infants with DGS, those with Zellweger syndrome typically have hepatomegaly that is associated with cirrhosis and biliary dysgenesis. (See
         <a class="medical medical_review" href="/z/d/html/6147.html" rel="external">
          "Peroxisomal disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25718611">
         <span class="h3">
          CHARGE syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants with the CHARGE association share phenotypic features with patients with 22qDS, including cardiac defects, cleft palate, and hearing loss [
         <a href="#rid73">
          73-75
         </a>
         ]. CHARGE is distinguished from DGS, however, by coloboma, choanal atresia, genital anomalies, and lack of 22q11.2 deletion.
        </p>
        <p>
         One report described a patient with CHARGE syndrome and profound T cell lymphopenia [
         <a href="#rid76">
          76
         </a>
         ]. A genetic variant in the
         <em>
          CHD7
         </em>
         gene was identified in this patient. A pathogenic variant in
         <em>
          CHD7
         </em>
         is found in approximately 70 percent of patients fulfilling the criteria for CHARGE, and this report provided the first link between
         <em>
          CHD7
         </em>
         variants and T cell lymphopenia. Subsequently, five patients were described with
         <em>
          CHD7
         </em>
         pathogenic variants and a complete DGS phenotype (T-B+NK+ severe combined immunodeficiency [SCID] and Omenn syndrome) [
         <a href="#rid77">
          77,78
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">
          "Severe combined immunodeficiency (SCID): An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">
          "Severe combined immunodeficiency (SCID): Specific defects"
         </a>
         .)
        </p>
        <p>
         A retrospective analysis of 25 patients with CHARGE association and confirmed
         <em>
          CHD7
         </em>
         pathogenic variants described a spectrum of immunodeficiencies in the majority of this cohort [
         <a href="#rid79">
          79
         </a>
         ]. The incidence of lymphopenia was higher in the CHARGE association cohort compared with the 22q11.2 cohort, suggesting that immunologists should be part of the treatment team for CHARGE association patients.
        </p>
        <p class="headingAnchor" id="H25718618">
         <span class="h3">
          Opitz G/BBB syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The Opitz G/BBB syndrome is characterized by ocular hypertelorism, asymmetry of the skull, hypospadias, and laryngoesophageal defects [
         <a href="#rid80">
          80
         </a>
         ]. These features distinguish Opitz G/BBB from DGS. The genetic basis for Opitz G/BBB remains poorly characterized. However, several patients have been described with 22q11.2 microdeletions [
         <a href="#rid81">
          81
         </a>
         ]. More sensitive genetic analysis in one patient with Opitz-like syndrome phenotype and 22q11.2 microdeletion demonstrated that this patient shared the same deletions as patients with DGS [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5813.html" rel="external">
          "Causes of primary adrenal insufficiency in children", section on 'Disorders of steroidogenesis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1431882">
         <span class="h3">
          Severe combined immunodeficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various forms of SCID (eg, Omenn syndrome, SCID with maternal T cell engraftment) should be excluded in patients with suspected atypical complete DGS since immune corrective therapies (thymic tissue implantation versus hematopoietic cell transplantation) and favorable outcomes vary greatly. (See
         <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">
          "Severe combined immunodeficiency (SCID): An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3912.html" rel="external">
          "Severe combined immunodeficiency (SCID): Specific defects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25718625">
         <span class="h2">
          Teratogen exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Phenotypically similar patients have been described secondary to several in utero exposures, such as
         <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">
          isotretinoin
         </a>
         or ethanol, or maternal conditions, such as diabetes [
         <a href="#rid72">
          72,83
         </a>
         ]. In these cases, genetic abnormalities have not been identified, and the phenotypic similarities are presumably a result of teratogen exposure at key developmental periods of neural crest cell migration.
        </p>
        <p class="headingAnchor" id="H643929380">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">
          "Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3601732">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Typical genotype and phenotype
         </strong>
         – Most cases of DiGeorge syndrome (DGS) are caused by a 22q11.2 deletion. The classic triad of features of DGS on presentation is conotruncal cardiac anomalies, hypoplastic thymus, and hypocalcemia, although the phenotype is variable  (
         <a class="graphic graphic_table graphicRef72911" href="/z/d/graphic/72911.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef54237" href="/z/d/graphic/54237.html" rel="external">
          table 2
         </a>
         ). Palatal abnormalities and developmental delay are common. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunodeficiency
         </strong>
         – Immunodeficiency is common in patients with DGS and can range from recurrent sinopulmonary infections (partial DGS) to congenital athymia with severe combined immunodeficiency (SCID) like phenotype (complete DGS). In general, the severity of the immunodeficiency is related to the degree of thymic hypoplasia. (See
         <a class="local">
          'Immunodeficiency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional clinical features
         </strong>
         – Other features of DGS that present outside of infancy and into adulthood include recurrent infections, autoimmunity, developmental delay, psychiatric abnormalities, and chronic inflammatory diseases  (
         <a class="graphic graphic_table graphicRef72911" href="/z/d/graphic/72911.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical presentation'
         </a>
         above and
         <a class="local">
          'Findings in adults'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation in neonates
         </strong>
         – The diagnosis of and evaluation for DGS should occur for any neonate with a conotruncal heart lesion, hypocalcemia, and/or cleft palate. This evaluation should proceed urgently since clinical manifestations in the neonate can be life threatening in the short term. (See
         <a class="local">
          'Evaluation in neonates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation in children and adults
         </strong>
         – The diagnosis should be considered in older children and adults with a family history of DGS or consistent clinical findings  (
         <a class="graphic graphic_table graphicRef72911" href="/z/d/graphic/72911.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef54237" href="/z/d/graphic/54237.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Evaluation in older children and adults'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of DGS is based upon reduced numbers of CD3+ T cells, combined with either characteristic clinical findings or a demonstrated deletion in chromosome 22q11.2  (
         <a class="graphic graphic_table graphicRef55190" href="/z/d/graphic/55190.html" rel="external">
          table 3
         </a>
         ). Criteria have been proposed for definite, probable, and possible DGS. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis includes exposure to teratogens and other congenital syndromes with similar clinical features. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2825692079">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bassett AS, McDonald-McGinn DM, Devriendt K, et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 2011; 159:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore) 2011; 90:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan AK, Goodship JA, Wilson DI, et al. Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study. J Med Genet 1997; 34:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vantrappen G, Devriendt K, Swillen A, et al. Presenting symptoms and clinical features in 130 patients with the velo-cardio-facial syndrome. The Leuven experience. Genet Couns 1999; 10:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald-McGinn DM, Kirschner R, Goldmuntz E, et al. The Philadelphia story: the 22q11.2 deletion: report on 250 patients. Genet Couns 1999; 10:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motzkin B, Marion R, Goldberg R, et al. Variable phenotypes in velocardiofacial syndrome with chromosomal deletion. J Pediatr 1993; 123:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cirillo E, Giardino G, Gallo V, et al. Intergenerational and intrafamilial phenotypic variability in 22q11.2 deletion syndrome subjects. BMC Med Genet 2014; 15:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald-McGinn DM, LaRossa D, Goldmuntz E, et al. The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patients. Genet Test 1997; 1:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldmuntz E, Driscoll DA, Emanuel BS, et al. Evaluation of potential modifiers of the cardiac phenotype in the 22q11.2 deletion syndrome. Birth Defects Res A Clin Mol Teratol 2009; 85:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiéronimus S, Bec-Roche M, Pedeutour F, et al. The spectrum of parathyroid gland dysfunction associated with the microdeletion 22q11. Eur J Endocrinol 2006; 155:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kar PS, Ogoe B, Poole R, Meeking D. Di-George syndrome presenting with hypocalcaemia in adulthood: two case reports and a review. J Clin Pathol 2005; 58:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris JM, Hazenberg MD, Poulin JF, et al. Multiparameter evaluation of human thymic function: interpretations and caveats. Clin Immunol 2005; 115:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolte L, Dreves AM, Ersbøll AK, et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2002; 185:1578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dou Y, Schindewolf E, Crowley TB, et al. The Association of Fetal Thymus Size with Subsequent T Cell Counts in 22q11.2 Deletion Syndrome. J Clin Immunol 2020; 40:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markert ML, Devlin BH, Alexieff MJ, et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood 2007; 109:4539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 2014; 312:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol 2015; 39:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markert ML, Alexieff MJ, Li J, et al. Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome. Blood 2004; 104:2574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ozcan E, Notarangelo LD, Geha RS. Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 2008; 122:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markert ML, Alexieff MJ, Li J, et al. Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol 2004; 113:734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vu QV, Wada T, Toma T, et al. Clinical and immunophenotypic features of atypical complete DiGeorge syndrome. Pediatr Int 2013; 55:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selim MA, Markert ML, Burchette JL, et al. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol 2008; 35:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piliero LM, Sanford AN, McDonald-McGinn DM, et al. T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome. Blood 2004; 103:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finocchi A, Di Cesare S, Romiti ML, et al. Humoral immune responses and CD27+ B cells in children with DiGeorge syndrome (22q11.2 deletion syndrome). Pediatr Allergy Immunol 2006; 17:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan KE, Jawad AF, Randall P, et al. Lack of correlation between impaired T cell production, immunodeficiency, and other phenotypic features in chromosome 22q11.2 deletion syndromes. Clin Immunol Immunopathol 1998; 86:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gennery AR. Immunological aspects of 22q11.2 deletion syndrome. Cell Mol Life Sci 2012; 69:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gennery AR, Barge D, O'Sullivan JJ, et al. Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome. Arch Dis Child 2002; 86:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CA, Driscoll DA, Emanuel BS, et al. Increased prevalence of immunoglobulin A deficiency in patients with the chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Diagn Lab Immunol 1998; 5:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jawad AF, McDonald-Mcginn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). J Pediatr 2001; 139:715.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schubert MS, Moss RB. Selective polysaccharide antibody deficiency in familial DiGeorge syndrome. Ann Allergy 1992; 69:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Segni M, Zimmerman D. Autoimmune hyperthyroidism in two adolescents with DiGeorge/velocardiofacial syndrome (22q11 deletion). Eur J Pediatr 2002; 161:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kratz CP, Niehues T, Lyding S, et al. Evans syndrome in a patient with chromosome 22q11.2 deletion syndrome: a case report. Pediatr Hematol Oncol 2003; 20:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruno B, Barbier C, Lambilliotte A, et al. Auto-immune pancytopenia in a child with DiGeorge syndrome. Eur J Pediatr 2002; 161:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tison BE, Nicholas SK, Abramson SL, et al. Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome. J Allergy Clin Immunol 2011; 128:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi JH, Shin YL, Kim GH, et al. Endocrine manifestations of chromosome 22q11.2 microdeletion syndrome. Horm Res 2005; 63:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies K, Stiehm ER, Woo P, Murray KJ. Juvenile idiopathic polyarticular arthritis and IgA deficiency in the 22q11 deletion syndrome. J Rheumatol 2001; 28:2326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancrini C, Puliafito P, Digilio MC, et al. Clinical features and follow-up in patients with 22q11.2 deletion syndrome. J Pediatr 2014; 164:1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giardino G, Cirillo E, Maio F, et al. Gastrointestinal involvement in patients affected with 22q11.2 deletion syndrome. Scand J Gastroenterol 2014; 49:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chinen J, Rosenblatt HM, Smith EO, et al. Long-term assessment of T-cell populations in DiGeorge syndrome. J Allergy Clin Immunol 2003; 111:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zemble R, Luning Prak E, McDonald K, et al. Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Clin Immunol 2010; 136:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrando-Martínez S, Lorente R, Gurbindo D, et al. Low thymic output, peripheral homeostasis deregulation, and hastened regulatory T cells differentiation in children with 22q11.2 deletion syndrome. J Pediatr 2014; 164:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klocperk A, Grecová J, Šišmová K, et al. Helios expression in T-regulatory cells in patients with di George Syndrome. J Clin Immunol 2014; 34:864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLean-Tooke A, Barge D, Spickett GP, Gennery AR. Immunologic defects in 22q11.2 deletion syndrome. J Allergy Clin Immunol 2008; 122:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montin D, Marolda A, Licciardi F, et al. Immunophenotype Anomalies Predict the Development of Autoimmune Cytopenia in 22q11.2 Deletion Syndrome. J Allergy Clin Immunol Pract 2019; 7:2369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies JK, Telfer P, Cavenagh JD, et al. Autoimmune cytopenias in the 22q11.2 deletion syndrome. Clin Lab Haematol 2003; 25:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DePiero AD, Lourie EM, Berman BW, et al. Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome. J Pediatr 1997; 131:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Staple L, Andrews T, McDonald-McGinn D, et al. Allergies in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome) and patients with chronic granulomatous disease. Pediatr Allergy Immunol 2005; 16:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruszka P, Addissie YA, McGinn DE, et al. 22q11.2 deletion syndrome in diverse populations. Am J Med Genet A 2017; 173:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yagi H, Furutani Y, Hamada H, et al. Role of TBX1 in human del22q11.2 syndrome. Lancet 2003; 362:1366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emanuel BS, McDonald-McGinn D, Saitta SC, Zackai EH. The 22q11.2 deletion syndrome. Adv Pediatr 2001; 48:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leopold C, De Barros A, Cellier C, et al. Laryngeal abnormalities are frequent in the 22q11 deletion syndrome. Int J Pediatr Otorhinolaryngol 2012; 76:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Widdershoven JC, Spruijt NE, Spliet WG, et al. Histology of the pharyngeal constrictor muscle in 22q11.2 deletion syndrome and non-syndromic children with velopharyngeal insufficiency. PLoS One 2011; 6:e21672.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swillen A, Devriendt K, Legius E, et al. Intelligence and psychosocial adjustment in velocardiofacial syndrome: a study of 37 children and adolescents with VCFS. J Med Genet 1997; 34:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerdes M, Solot C, Wang PP, et al. Cognitive and behavior profile of preschool children with chromosome 22q11.2 deletion. Am J Med Genet 1999; 85:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss EM, Batshaw ML, Solot CB, et al. Psychoeducational profile of the 22q11.2 microdeletion: A complex pattern. J Pediatr 1999; 134:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang PP, Woodin MF, Kreps-Falk R, Moss EM. Research on behavioral phenotypes: velocardiofacial syndrome (deletion 22q11.2). Dev Med Child Neurol 2000; 42:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Aken K, De Smedt B, Van Roie A, et al. Motor development in school-aged children with 22q11 deletion (velocardiofacial/DiGeorge syndrome). Dev Med Child Neurol 2007; 49:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vorstman JA, Breetvelt EJ, Duijff SN, et al. Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. JAMA Psychiatry 2015; 72:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devriendt K, Swillen A, Fryns JP, et al. Renal and urological tract malformations caused by a 22q11 deletion. J Med Genet 1996; 33:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bassett AS, Chow EW, Husted J, et al. Clinical features of 78 adults with 22q11 Deletion Syndrome. Am J Med Genet A 2005; 138:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen E, Chow EW, Weksberg R, Bassett AS. Phenotype of adults with the 22q11 deletion syndrome: A review. Am J Med Genet 1999; 86:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van L, Heung T, Graffi J, et al. All-cause mortality and survival in adults with 22q11.2 deletion syndrome. Genet Med 2019; 21:2328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999; 93:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleveland WW. Immunologic reconstitution in the DiGeorge syndrome by fetal thymic transplant. Birth Defects Orig Artic Ser 1975; 11:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markert ML, Boeck A, Hale LP, et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N Engl J Med 1999; 341:1180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lingman Framme J, Borte S, von Döbeln U, et al. Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome. J Clin Immunol 2014; 34:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pretto D, Maar D, Yrigollen CM, et al. Screening newborn blood spots for 22q11.2 deletion syndrome using multiplex droplet digital PCR. Clin Chem 2015; 61:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knutsen AP, Baker MW, Markert ML. Interpreting low T-cell receptor excision circles in newborns with DiGeorge anomaly: importance of assessing naive T-cell markers. J Allergy Clin Immunol 2011; 128:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogels A, Schevenels S, Cayenberghs R, et al. Presenting symptoms in adults with the 22q11 deletion syndrome. Eur J Med Genet 2014; 57:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu AP, Chow PC, Lee PP, et al. Under-recognition of 22q11.2 deletion in adult Chinese patients with conotruncal anomalies: implications in transitional care. Eur J Med Genet 2014; 57:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jalali GR, Vorstman JA, Errami A, et al. Detailed analysis of 22q11.2 with a high density MLPA probe set. Hum Mutat 2008; 29:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg F. DiGeorge syndrome: an historical review of clinical and cytogenetic features. J Med Genet 1993; 30:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devriendt K, Swillen A, Fryns JP. Deletion in chromosome region 22q11 in a child with CHARGE association. Clin Genet 1998; 53:408.
          </a>
         </li>
         <li class="breakAll">
          Online Medelian Inheritance in Man (OMIM) database. www.ncbi.nlm.nih.gov (Accessed on March 29, 2007).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanlaville D, Verloes A. CHARGE syndrome: an update. Eur J Hum Genet 2007; 15:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanka M, Tangsinmankong N, Loscalzo M, et al. Complete DiGeorge syndrome associated with CHD7 mutation. J Allergy Clin Immunol 2007; 120:952.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inoue H, Takada H, Kusuda T, et al. Successful cord blood transplantation for a CHARGE syndrome with CHD7 mutation showing DiGeorge sequence including hypoparathyroidism. Eur J Pediatr 2010; 169:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gennery AR, Slatter MA, Rice J, et al. Mutations in CHD7 in patients with CHARGE syndrome cause T-B + natural killer cell + severe combined immune deficiency and may cause Omenn-like syndrome. Clin Exp Immunol 2008; 153:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jyonouchi S, McDonald-McGinn DM, Bale S, et al. CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features. Pediatrics 2009; 123:e871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quaderi NA, Schweiger S, Gaudenz K, et al. Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22. Nat Genet 1997; 17:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonald-McGinn DM, Driscoll DA, Bason L, et al. Autosomal dominant "Opitz" GBBB syndrome due to a 22q11.2 deletion. Am J Med Genet 1995; 59:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erickson RP, Díaz de Ståhl T, Bruder CE, Dumanski JP. A patient with 22q11.2 deletion and Opitz syndrome-like phenotype has the same deletion as velocardiofacial patients. Am J Med Genet A 2007; 143A:3302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ammann AJ, Wara DW, Cowan MJ, et al. The DiGeorge syndrome and the fetal alcohol syndrome. Am J Dis Child 1982; 136:906.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 83396 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21570089" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Practical guidelines for managing patients with 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21200182" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9350810" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Spectrum of clinical features associated with interstitial chromosome 22q11 deletions: a European collaborative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10191424" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Presenting symptoms and clinical features in 130 patients with the velo-cardio-facial syndrome. The Leuven experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10191425" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The Philadelphia story: the 22q11.2 deletion: report on 250 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8355116" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Variable phenotypes in velocardiofacial syndrome with chromosomal deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24383682" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Intergenerational and intrafamilial phenotypic variability in 22q11.2 deletion syndrome subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10464633" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18770859" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Evaluation of potential modifiers of the cardiac phenotype in the 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16793949" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The spectrum of parathyroid gland dysfunction associated with the microdeletion 22q11.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15917421" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Di-George syndrome presenting with hypocalcaemia in adulthood: two case reports and a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15885636" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Multiparameter evaluation of human thymic function: interpretations and caveats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12023763" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32583204" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The Association of Fetal Thymus Size with Subsequent T Cell Counts in 22q11.2 Deletion Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17284531" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25138334" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25937517" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : History and current status of newborn screening for severe combined immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15100156" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19084106" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Primary immune deficiencies with aberrant IgE production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15100681" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22978387" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical and immunophenotypic features of atypical complete DiGeorge syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18333898" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14525774" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : T-cell homeostasis in humans with thymic hypoplasia due to chromosome 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16846458" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Humoral immune responses and CD27+ B cells in children with DiGeorge syndrome (22q11.2 deletion syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9473376" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lack of correlation between impaired T cell production, immunodeficiency, and other phenotypic features in chromosome 22q11.2 deletion syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21984609" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Immunological aspects of 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12023174" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9606003" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Increased prevalence of immunoglobulin A deficiency in patients with the chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11713452" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1524280" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Selective polysaccharide antibody deficiency in familial DiGeorge syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12014397" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Autoimmune hyperthyroidism in two adolescents with DiGeorge/velocardiofacial syndrome (22q11 deletion).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12554529" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Evans syndrome in a patient with chromosome 22q11.2 deletion syndrome: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12111192" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Auto-immune pancytopenia in a child with DiGeorge syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21835443" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15995343" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Endocrine manifestations of chromosome 22q11.2 microdeletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11669177" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Juvenile idiopathic polyarticular arthritis and IgA deficiency in the 22q11 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24657119" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical features and follow-up in patients with 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24344832" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Gastrointestinal involvement in patients affected with 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12642839" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Long-term assessment of T-cell populations in DiGeorge syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20472505" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24461789" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Low thymic output, peripheral homeostasis deregulation, and hastened regulatory T cells differentiation in children with 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25008482" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Helios expression in T-regulatory cells in patients with di George Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18485468" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Immunologic defects in 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30922987" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Immunophenotype Anomalies Predict the Development of Autoimmune Cytopenia in 22q11.2 Deletion Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12755799" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Autoimmune cytopenias in the 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329436" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15853951" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Allergies in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome) and patients with chronic granulomatous disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28328118" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : 22q11.2 deletion syndrome in diverse populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14585638" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Role of TBX1 in human del22q11.2 syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11480765" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22019154" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Laryngeal abnormalities are frequent in the 22q11 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21738760" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Histology of the pharyngeal constrictor muscle in 22q11.2 deletion syndrome and non-syndromic children with velopharyngeal insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9192263" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Intelligence and psychosocial adjustment in velocardiofacial syndrome: a study of 37 children and adolescents with VCFS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10406665" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cognitive and behavior profile of preschool children with chromosome 22q11.2 deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9931529" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Psychoeducational profile of the 22q11.2 microdeletion: A complex pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10875531" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Research on behavioral phenotypes: velocardiofacial syndrome (deletion 22q11.2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17355478" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Motor development in school-aged children with 22q11 deletion (velocardiofacial/DiGeorge syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25715178" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8730297" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Renal and urological tract malformations caused by a 22q11 deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16208694" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clinical features of 78 adults with 22q11 Deletion Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10494092" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Phenotype of adults with the 22q11 deletion syndrome: A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30948858" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : All-cause mortality and survival in adults with 22q11.2 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10600329" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1148386" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Immunologic reconstitution in the DiGeorge syndrome by fetal thymic transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10523153" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Transplantation of thymus tissue in complete DiGeorge syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24610337" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Retrospective analysis of TREC based newborn screening results and clinical phenotypes in infants with the 22q11 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25388430" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Screening newborn blood spots for 22q11.2 deletion syndrome using multiplex droplet digital PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22018899" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Interpreting low T-cell receptor excision circles in newborns with DiGeorge anomaly: importance of assessing naive T-cell markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24576609" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Presenting symptoms in adults with the 22q11 deletion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24721633" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Under-recognition of 22q11.2 deletion in adult Chinese patients with conotruncal anomalies: implications in transitional care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18033723" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Detailed analysis of 22q11.2 with a high density MLPA probe set.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8230154" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : DiGeorge syndrome: an historical review of clinical and cytogenetic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9660062" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Deletion in chromosome region 22q11 in a child with CHARGE association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9660062" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Deletion in chromosome region 22q11 in a child with CHARGE association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17299439" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : CHARGE syndrome: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17931565" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Complete DiGeorge syndrome associated with CHD7 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20052490" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Successful cord blood transplantation for a CHARGE syndrome with CHD7 mutation showing DiGeorge sequence including hypoparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18505430" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Mutations in CHD7 in patients with CHARGE syndrome cause T-B + natural killer cell + severe combined immune deficiency and may cause Omenn-like syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19403480" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : CHARGE (coloboma, heart defect, atresia choanae, retarded growth and development, genital hypoplasia, ear anomalies/deafness) syndrome and chromosome 22q11.2 deletion syndrome: a comparison of immunologic and nonimmunologic phenotypic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9354791" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8849001" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Autosomal dominant "Opitz" GBBB syndrome due to a 22q11.2 deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18000907" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A patient with 22q11.2 deletion and Opitz syndrome-like phenotype has the same deletion as velocardiofacial patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6812410" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The DiGeorge syndrome and the fetal alcohol syndrome.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
